Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13491690 | 0.87 | MAPK1 (0.48) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL7018581 | 0.85 | NPC1 (0.73) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL7013158 | 0.82 | LMNA (0.53) | LMNANPC1RAB9AMEN1KMT2A | |
| SCHEMBL7016468 | 0.82 | MEN1 (0.74) | LMNAMEN1KMT2APOLBMAOB | |
| SCHEMBL7017456 | 0.82 | POLB (0.64) | NPC1RAB9APOLBHPGD | |
| SCHEMBL7014523 | 0.82 | MEN1 (0.55) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL13491655 | 0.81 | KMT2A (0.55) | KMT2APOLBTP53 | |
| SCHEMBL13781698 | 0.81 | MEN1 (0.59) | LMNANPC1RAB9AMEN1KMT2A | |
| SCHEMBL13491626 | 0.81 | MEN1 (0.48) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL5090143 | 0.80 | NPC1 (0.55) | LMNANPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605614-B2 | Anti-hepatitis or anti-herpes | BIOCHEM PHARMA INC. (CA) | 2003-08-12 | — | — | US | claimed |
| EP-1155017-B1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | SHIRE BIOCHEM INC (CA) | 2003-01-15 | — | — | EP | claimed |
| JP-2002537396-A | — | — | 2002-11-05 | — | — | JP | claimed |
| US-20020099072-A1 | [1,8] naphthyridine derivatives having antiviral activity | BIOCHEM PHARMA INC. | 2002-07-25 | — | — | US | claimed |
| US-6340690-B1 | INHIBITING HEPATITIS OR HERPES VIRAL INFECTIONS | BIO-CHEM PHARMA INC. (CA) | 2002-01-22 | — | — | US | claimed |
| EP-1155017-A1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | Shire Biochem Inc. (CA) | 2001-11-21 | — | — | EP | claimed |
| WO-2000050424-A1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | BIOCHEM PHARMA INC. (CA) | 2000-08-31 | — | — | WO | claimed |
| US-6605614-B2 | Anti-hepatitis or anti-herpes | BIOCHEM PHARMA INC. (CA) | 2003-08-12 | — | — | US | disclosed |
| EP-1155017-B1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | SHIRE BIOCHEM INC (CA) | 2003-01-15 | — | — | EP | disclosed |
| US-20020099072-A1 | [1,8] naphthyridine derivatives having antiviral activity | BIOCHEM PHARMA INC. | 2002-07-25 | — | — | US | disclosed |
| US-6340690-B1 | INHIBITING HEPATITIS OR HERPES VIRAL INFECTIONS | BIO-CHEM PHARMA INC. (CA) | 2002-01-22 | — | — | US | disclosed |
| EP-1155017-A1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | Shire Biochem Inc. (CA) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050424-A1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | BIOCHEM PHARMA INC. (CA) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099072-A1 | [1,8] naphthyridine derivatives having antiviral activity | HAVCR2, MAVS, NTPCR | LMNA 1578/4885NPC1 67/4885RAB9A 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.